Lantern Pharma has successfully completed its Phase 1a trial of LP-184, meeting all primary endpoints with a favorable safety profile and early signs of antitumor activity. The open-label study in 63 patients with advanced relapsed or refractory solid tumors, including glioblastoma, showed disease control in 48 percent of evaluable patients at therapeutic dose levels.
